Target: CD183.
Clone: CXCR3-173.
Specificity: CXCR3-173 activity is directed against murine CD183 (CXCR3).
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: CXCL3 is expressed on primary memory phenotype CD4+ and CD8+ T cells, naturally occurring CD4+CD25+ Foxp3+ regulatory T cells, natural killer (NK) T cells, and approximately 25% of NK cells. CXCR3-173 recognizes an epitope of CXCR3 expressed on the surface of activated mouse splenocytes.
Background: Hamsters were tested by ELISA for seropositivity against CXCR3 peptide and hybridomas were generated, screened by FACS, purified, and tested for: staining, CXCR3 blockade in vitro, and endotoxin levels. CXCR3-173 detects the native form of CXCR3, and therefore does not work in Western blotting.CXCR3-173 has potential use in immunotherapeutic approaches to inhibit transplant rejection and immune related diseases. In vitro, CXCR3-173 blocks chemotaxis in response to CXCL10 or CXCL11 but not CXCL9. In vivo, CXCR3-173 prolongs both cardiac and islet allograft survival in a manner further enhanced by rapamycin.
Immunogen: CXCR3-173 was generated by immunizing Armenian hamsters with a peptide sequence unique to mouse CXCR3 which encompasses amino acids 1-37.
Concentration: ≥ 2.0 mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: <1.0 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
